Biologic therapy for dyslipidemia

Autor:	David Karasek
Rok vydání:	2021
Předmět:	business.industry Lipoproteins Evinacumab Mipomersen medicine.disease Bioinformatics Biological Therapy Pharmacotherapy Inclisiran Internal Medicine medicine Humans Proprotein Convertase 9 Cardiology and Cardiovascular Medicine business PCSK9 Inhibitors Dyslipidemia Dyslipidemias
Zdroj:	Vnitřní lékařství. 67:206-211
ISSN:	1801-7592 0042-773X
DOI:	10.36290/vnl.2021.054
Popis:	Dyslipidemia treatment represents a very dynamically growing segment of pharmacotherapy, including a production of biological agents. Nowadays, they are targeting at various proteins that are involved in the synthesis, transport, or metabolism of lipoproteins. This review provides a statement of current options for the biological treatment of dyslipidemias and for other products that have the potential to broaden its spectrum in the near future.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11404599141c3b2e3b300d325d05644a https://doi.org/10.36290/vnl.2021.054 Zobrazit plný text záznamu